NVS Oct 2024 110.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 02:33PM EDT
Loading interactive chart…
- Zacks
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
- Zacks
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- GlobeNewswire
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CESTTransaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-s
© 2024 Yahoo. All rights reserved.